Untoward Reactions Following Toxin Treatment for Dermatitis Venenata

Templeton, H. J.

doi:10.1001/archderm.1929.01440010091011

Cited by 13 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 1929, Templeton reported on further cases of adverse effects (disseminated urticaria and eczema) to this therapy [75]. Altogether, when looking at the overview of clinical studies on immunotherapy with Rhus extracts (collated in Table 2), it is hard to escape the impression that the poorer was the design of a trial (e.g., lack of placebo control and no objective outcome measures), the more the final conclusions were in favor of Rhus desensitization.…”

Section: Clinical Trials Of Immunotherapy With Haptensmentioning

confidence: 99%

Immunotherapy of Allergic Contact Dermatitis

Śpiewak

2011

Immunotherapy

View full text Add to dashboard Cite

The term 'immunotherapy' refers to treating diseases by inducing, enhancing or suppressing immune responses. As allergy is an excessive, detrimental immune reaction to otherwise harmless environmental substances, immunotherapy of allergic disease is aimed at the induction of tolerance toward sensitizing antigens. This article focuses on the historical developments, present state and future outlook for immunotherapy with haptens as a therapeutic modality for allergic contact dermatitis. Inspired by the effectiveness of immunotherapy in respiratory allergies, attempts were undertaken at curing allergic contact dermatitis by means of controlled administration of the sensitizing haptens. Animal and human experiments confirmed that tolerance to haptens can be induced most effectively when the induction of tolerance precedes attempted sensitization. In real life, however, therapy is sought by people who are already sensitized and an effective reversal of hypersensitivity seems more difficult to achieve. Decades of research on Rhus hypersensitivity led to a conclusion that immunotherapy can suppress Rhus dermatitis, however, only to a limited degree, for a short period of time, and at a high risk of side effects, which makes this method therapeutically unprofitable. Methodological problems with most available studies of immunotherapy of contact allergy to nickel make any definite conclusions impossible at this stage.

show abstract

Section: Clinical Trials Of Immunotherapy With Haptensmentioning

confidence: 99%